62 results about "Neurologic function" patented technology

Disclosed herein are of systems, methods, and computer-program products for determining if a response is an electrically evoked compound action potential (eCAP), refining raw data of an eCAP amplitude growth function (AGF) and utilizing maximum (i.e., steepest) slope from moving linear regression to effectively estimate cochlear nerve function, and determining quality of an electrode-neuron interface (ENI) using a model developed from eCAP attributes.

This disclosure provides a monitoring and early warning system and computer device for stroke revascularization surgery; including: an acquisition module for acquiring a first set of neuroelectrophysiological data and a second set of neuroelectrophysiological data; a first processing module for obtaining a first impairment level characterizing the preoperative neurological function impairment based on the differences between the physiological data of the first affected side and the physiological data of the first healthy side at the same time point in the first set of neuroelectrophysiological data; a second processing module for obtaining a second impairment level characterizing the postoperative neurological function impairment based on the differences between the physiological data of the second affected side and the physiological data of the second healthy side at the same time point in the second set of neuroelectrophysiological data; and a prediction module for predicting the probability of various complications within a predicted postoperative time period. By comparing and analyzing the preoperative and postoperative neuroelectrophysiological data of the affected / healthy side, the risk of complications after revascularization surgery can be predicted.

This invention relates to the field of stroke early warning technology, specifically to an intelligent early warning system and method for stroke window periods based on multiple vital signs. The system includes a vital sign acquisition module, a preprocessing module, a feature fusion module, a window period calibration module, an early warning module, and a linkage module. The method includes multi-dimensional vital sign data acquisition, preprocessing, feature fusion, dynamic window period calibration, graded early warning, and linkage intervention steps. This invention collects multi-dimensional vital sign data on routine physiological, neurological, metabolic, and microcirculatory functions. It employs adaptive threshold denoising to remove false features, combines a dynamic weight fusion algorithm to achieve deep fusion of multiple vital sign features, and utilizes an improved BP neural network combined with individual baselines and risk factors to dynamically calibrate the early warning window period. This addresses the problems of low early warning accuracy, ambiguous window period judgment, lack of individual adaptability, and lack of effective linkage intervention after early warning in existing technologies, achieving accurate and timely early warning of stroke window periods.

This invention relates to a pharmaceutical composition and its application for treating acute ischemic stroke. The pharmaceutical composition for treating acute ischemic stroke comprises separately packaged tissue-type plasminogen activator citPA5 and a platelet aggregation inhibitor. Its beneficial effects include significantly improving cerebral blood flow recovery, shortening thrombolysis time, reducing infarct volume, and improving neurological function without increasing the risk of bleeding, demonstrating a good synergistic thrombolytic effect.

The application provides a traditional Chinese medicine preparation for treating or improving cerebral hemorrhage and a preparation method thereof, and relates to the technical field of traditional Chinese medicine pharmacy. The traditional Chinese medicine preparation is composed of nacre, antelope horn powder, dragon's blood, Herba Schizonepetae, Prunella vulgaris, Stink-bug, Smilax riparia, bamboo juice, dried tangerine or orange peel, clubmoss, radix puerariae, Zizania aquatica and leaf of Chinese pear. The preparation has a significant therapeutic effect on cerebral hemorrhage, can obviously improve the neurological deficit of cerebral hemorrhage rats, reduce the water content of brain tissue to alleviate brain edema, simultaneously alleviate the inflammatory response in the body, thereby playing a neuroprotective effect on cerebral hemorrhage rats. In addition, the preparation can obviously improve the consciousness state of cerebral hemorrhage patients, alleviate the degree of neurological deficit, relieve the related TCM syndromes of the patients, simultaneously effectively improve the daily life ability of the patients, significantly improve the total effective rate of clinical treatment, and no obvious adverse reactions are observed in the treatment process, and the safety is good, thereby providing a safe and effective treatment scheme for the conservative treatment of cerebral hemorrhage.

The application provides a kinase inhibitor leading compound, a virtual screening method thereof and application of the kinase inhibitor leading compound in preparation of branched-chain alpha-keto acid dehydrogenase kinase inhibitors and / or drugs for treating diseases mediated by branched-chain alpha-keto acid dehydrogenase kinase. The virtual screening method provided by the application combines various virtual screening platforms to screen a large-scale compound library, improves the true positive rate of screening results, reduces the number of compounds needing experimental screening, and saves screening time and cost. In addition, the compounds I-III screened out with good binding affinity to BCKDK can be used in researches on targeting BCKDK to treat major diseases such as obesity, insulin resistance, maple syrup urine disease, neurological dysfunction, liver cancer, colorectal cancer and tumor cachexia.

This invention discloses a traditional Chinese medicine nasal inhalation powder for facial meridian clearing and nasal closure, and its preparation method. The powder is prepared from the following raw materials in parts by weight: 5-10 parts musk, 12-17 parts angelica dahurica, 15-20 parts peppermint, 7-12 parts black sedge, 12-17 parts pearl, 15-20 parts asarum, and 10-30 parts soapberry. This traditional Chinese medicine nasal inhalation powder and its preparation method for facial meridian clearing and nasal closure exhibit multi-target synergistic effects. The effects of this invention are remarkable. The formula is scientific, with the various herbs working together. Musk and Asarum are the principal herbs, which have a strong effect of opening the orifices, refreshing the mind, dispelling wind and cold. Angelica dahurica and Gleditsia sinensis are the assistant herbs, which dispel wind and dry dampness and open the nasal passages. Zaocys dhumnades dispels wind and unblocks the meridians. Peppermint is cooling and dispersing. Pearl detoxifies and promotes tissue regeneration. Together, they assist the principal and assistant herbs in their effects. This combination can not only quickly relieve facial muscle spasms and numbness, but also improve local microcirculation and promote the recovery of nerve function. Nasal administration is fast-acting and takes effect by utilizing the rich vascular network and olfactory nerve pathway of the nasal mucosa.

The application relates to the technical field of medicines, and particularly discloses a polypeptide and application of the polypeptide in preparation of a medicine for ischemic stroke. The amino acid sequence of the polypeptide is as shown in SEQ ID NO. 1. The polypeptide can significantly improve the nerve function defect of a mouse transient middle cerebral artery occlusion / reperfusion (tMCAO / R) model in vivo, reduce the cerebral infarction volume, and reduce the whole-body oxidative stress level. In vitro, the polypeptide has a direct protective effect on HT22 cells of mouse hippocampal neurons and hCMEC / D3 cells of human brain microvascular endothelium induced by oxygen-glucose deprivation (OGD), can resist the damage of corticosterone and MPP + induced PC12 cells, and effectively inhibits the accumulation of reactive oxygen species (ROS) in cells. The results show that the polypeptide has a multi-target cell protection activity, can play an anti-ischemic stroke role from multiple dimensions such as reduction of infarction volume, inhibition of oxidative stress level, and protection of nerve vascular units.

This invention provides a traditional Chinese medicine compound preparation and its application in the preparation of drugs for treating cardiovascular and cerebrovascular diseases, belonging to the field of traditional Chinese medicine technology. The traditional Chinese medicine compound preparation comprises the following raw materials in parts by weight: 10-20 parts bee pollen, 8-15 parts curcumin, 5-10 parts γ-aminobutyric acid, 5-12 parts Litsea cubeba leaf, 10-20 parts hawthorn, 5-10 parts Lindera strychnifolia leaf, 10-20 parts kudzu root, 5-12 parts ginseng, 8-15 parts Polygonatum sibiricum, 6-12 parts Sophora japonica flower bud, 3-8 parts tangerine peel, and 1-5 parts L-cysteine. This invention significantly improves the water solubility, stability, and bioavailability of curcumin by constructing a chlorophyll zinc / LDH nanosheet composite carrier to load curcumin. A compound preparation of traditional Chinese medicine was prepared by combining a complex loaded with curcumin with various food and medicine homologous ingredients. This traditional Chinese medicine compound preparation can significantly reduce whole blood viscosity, plasma viscosity and platelet aggregation rate in rats with acute blood stasis model, has anti-thrombotic effect, and significantly promotes the recovery of neurological function in rats with focal cerebral ischemia and reduces the volume of cerebral infarction.

This invention provides the application of a nutritional composition in the preparation of products that promote neural development and support the improvement of neural function. The research of this invention found that intervention in the body using a nutritional composition comprising *Bifidobacterium animalis* subsp. *lactobacterium* CP-9 and 3'-sialic acid lactose can promote the development of amygdala neuronal structure, improve neural plasticity, and enhance synaptic function, thereby promoting the formation and functional maturation of the normal amygdala structure. As a core brain region regulating emotional responses, social cognition, and stress responses, the normal development of the amygdala plays a crucial role in an individual's emotional regulation ability, social interaction behavior, cognitive function, and mental health. Therefore, this invention promotes the structural and functional development of the amygdala through nutritional intervention, ultimately improving an individual's emotional regulation ability, social interaction behavior, cognitive function, and mental health.

This invention discloses the application of total small molecules of Polygonatum cyrtonema in the preparation of drugs for treating vascular dementia, belonging to the field of natural medicine technology. This invention obtains total small molecules of Polygonatum cyrtonema through a combination of water extraction and alcohol precipitation with macroporous adsorption resin purification. Experiments using a rat model of vascular dementia showed that these total small molecules of Polygonatum cyrtonema effectively improved the degree of neurological function impairment and learning and memory abilities in rats, indicating that the total small molecules of Polygonatum cyrtonema prepared by this invention can effectively treat vascular dementia, providing a new drug source and treatment method for clinical vascular dementia treatment.

The application discloses a waterproof and breathable type brain and spinal cord nerve injury wound protection dressing, which is sequentially stacked and arranged from inside to outside as a wound adhesion inner layer, a functional sustained-release middle layer and a waterproof and breathable outer layer; the three-layer synergistic dressing structure of the wound adhesion inner layer, the functional sustained-release middle layer and the waterproof and breathable outer layer is constructed, waterproof sealing and the dynamic adaptation of the air permeability performance of the brain and spinal cord nerve injury wound are realized, the target anti-scar polypeptide is covalently bonded on the inner layer, the effective inhibition of excessive scar hyperplasia and neuroma formation is realized, the matching regulation of the gradient degradation drug-loaded microsphere system and the air permeation pore size of the middle layer is realized, the accurate release of active factors in the whole cycle of nerve repair is realized, the long-acting waterproof and breathable protection in a dynamic scene is realized through the design of the outer layer of super-hydrophobic nanofiber membrane, the risk of postoperative complications is reduced, and the integration and synergy of the physical protection of the wound and the nerve function repair are realized.

The application provides a kind of affected side spatial stratification activation and multi-modal unilateral spatial neglect (USN) cognitive function evaluation and training intelligent system, aiming at solving the pain points such as low efficiency of evaluation, training homogeneity, effect difficult to transfer in USN patient rehabilitation, and building a whole-process intelligent rehabilitation system of "accurate evaluation-personalized training-dynamic optimization-effect transfer". Through the combination of rapid quantitative evaluation system, behavior data and electroencephalogram signal, the objective grading of USN severity is realized, which gets rid of artificial dependence and greatly improves the evaluation efficiency and accuracy; through the whole-process automatic operation and machine learning self-adaptive optimization, the operation cost of clinical personnel is reduced, the rehabilitation effect is traceable and evaluable, and an accurate and personalized intelligent rehabilitation system is built, which provides a whole-process solution for USN patients and has important significance for promoting the intelligent development of post-stroke neurological dysfunction rehabilitation.

This invention relates to the pharmaceutical field, specifically to the application of tissue inhibitor metalloproteinases-2 (TIMP2) in the preparation of drugs for the prevention or treatment of traumatic brain injury. TIMP2 protein can increase the fall latency in rotarod experiments in mice with traumatic brain injury; improve the motor balance ability of mice with traumatic brain injury on a balance beam; improve neurological function impairment in mice with traumatic brain injury; and reduce Evans blue permeability in brain tissue. In brain microvascular endothelial cells (HBMECs), TIMP2 protein can participate in maintaining the integrity of the endothelial barrier, reversing the loss of expression and altered localization of the connectome complex induced in an in vitro traumatic brain injury model, and reducing luciferase leakage. This invention also provides the application of TIMP2 protein as an Integrin α3β1 ligand in the preparation of drugs for the treatment of central nervous system diseases caused by blood-brain barrier dysfunction. TIMP2 protein exerts its function by binding to the cell membrane receptor Integrin α3β1, regulating VE-Cadherin phosphorylation. TIMP2 protein shows promising application prospects in the treatment of blood-brain barrier dysfunction caused by traumatic brain injury.

The application relates to the technical field of postoperative evaluation and rehabilitation of neurosurgery, and particularly relates to a postoperative evaluation system for neurosurgery based on machine learning. A multi-modal data acquisition module acquires clinical data of a patient; a cloud-edge federated learning module performs distributed machine learning analysis based on multi-source heterogeneous data; a brain-computer interface neural function evaluation module performs feature extraction and calculation, and outputs a quantitative evaluation result; a digital twin rehabilitation planning module constructs an individualized brain dynamic model and generates a personalized rehabilitation scheme; a data security and conformity module performs encryption processing, access control and conformity checking on data transmission and storage; a system integration and interface module is connected with an external medical device and converts protocols; a clinical verification and iteration module verifies the performance of a core model and updates parameters; and a user interaction and visualization module presents the quantitative evaluation result, the personalized rehabilitation scheme and provides an interactive interface. The application realizes precision, safety and personalization of postoperative evaluation and rehabilitation of neurosurgery.

A closed-loop microelectrode array for spinal cord nerve function repair based on 3D printing, its fabrication method, and its application are disclosed, solving the problems of signal interference, mechanical mismatch, and lack of closed-loop control in existing neuromodulation devices. The invention includes an electrode array base plate with several electrode supports mounted on it. The upper end face of the base plate serves as a mounting surface, and the electrode supports are densely arranged on this mounting surface. The end of each electrode support away from the base plate is an electrode group for direct contact with the spinal cord nerve. Each electrode support comprises, from the inside out, an electrophysiological recording microelectrode, a first dielectric layer, an inner ground microelectrode, a second dielectric layer, an electrical stimulation microelectrode, a third dielectric layer, an outer ground microelectrode, and a fourth dielectric layer. The upper end of the electrophysiological recording microelectrode, the first dielectric layer, the inner ground microelectrode, the second dielectric layer, the electrical stimulation microelectrode, the third dielectric layer, the outer ground microelectrode, and the fourth dielectric layer is the electrode group for direct contact with the spinal cord nerve.

The application provides a remote intraoperative neurophysiological monitoring method and system, first, a set of continuous neuroelectrophysiological waveform signals of a patient in an operation recorded synchronously through multiple monitoring leads is collected, then feature extraction is performed on the signal set to obtain a nerve function state feature containing waveform features and rhythm features, then remote real-time analysis is carried out on the nerve function state feature to generate an intraoperative nerve function monitoring result containing function stability information and abnormal fluctuation information, and the intraoperative nerve function monitoring result is transmitted to a remote monitoring terminal for dynamic display, finally, an intraoperative intervention prompt operation is triggered based on the abnormal fluctuation information to assist the operator to adjust the operation, thereby breaking through the spatial limitation of traditional intraoperative neuroelectrophysiological monitoring, fully utilizing high-quality medical resources, providing decision support for the operator in time, and reducing the risk of surgical nerve injury.

The present application relates to the technical field of medicine, especially relates to application of a small molecule compound LZ-09 in preparation of a medicine for treating and / or preventing multiple sclerosis. The present application adopts H2O2 damage OLN-93 cells as a nerve cell oxidative stress model, and the result shows that LZ-09 treatment significantly weakens the cell viability decrease caused by H2O2. The classic EAE model is made by using MOG35-55 to induce C57BL / 6 mice, and it is found that after LZ-09 intervention, the mouse neurological deficit symptom score is significantly reduced, and the disease progression is delayed, and spinal cord tissue HE and LFB staining find that the inflammation infiltration and demyelination are reduced. Therefore, the compound can effectively alleviate the symptoms of multiple sclerosis, can be used as a medicine for treating multiple sclerosis, and has wide development and application prospect.

The application discloses application of bupropion hydrochloride tablets (75mg) in preparation of a medicine for treating stroke, and belongs to the technical field of new purposes of medicines. The core verifies the efficacy and safety of the medicine of the specification through systematic animal tests, aims at the problems of post-stroke neural function defect, motor dysfunction and insufficient neural plasticity, adopts a line plug method to prepare a rat focal cerebral ischemia (MCAO) model, sets multiple control tests, and explores the dosing effect of an equivalent dose of the bupropion hydrochloride tablets (75mg). The test results show that the medicine can significantly reduce the neural function defect score of the model animals, improve the motor coordination ability and the limb usage rate, increase the content of brain-derived neurotrophic factor (BDNF) in the brain, promote the repair of neural plasticity, and is safer than a high-dose scheme and has no obvious adverse reactions. Through complete animal test data, the application proves the effectiveness and safety of the bupropion hydrochloride tablets (75mg) in treating stroke, provides solid test basis for clinical conversion and application of the bupropion hydrochloride tablets (75mg), and has important medical application value.

This invention provides a composite composition containing nervonic acid and its use in brain nerve repair, belonging to the field of biotechnology. The invention uses nervonic acid and phosphatidylserine, combined with plant extracts fermented by a microbial concoction of *Lactobacillus acidophilus*: *Lactobacillus rhamnosus*: *Bacillus belyssae* = (2-3):1:1, to form a composite composition. This scientific formulation achieves synergistic effects from multiple components, improving neurological deficits, reducing cerebral infarction volume, decreasing the release of neurotrophic markers, and upregulating neurotrophic factor expression through multi-target synergistic effects. Furthermore, this synergistic effect depends on specific component ratios, providing crucial experimental support for the development of subsequent brain-protective functional compositions. This composition can be widely applied to the preparation of brain nerve repair drugs, functional foods, and dietary supplements, possessing promising industrialization prospects and clinical value.

The application relates to application of CTRP4 in condition assessment and treatment of herpes simplex encephalitis, belongs to the technical field of biological medicine, and solves one of the problems that the condition assessment of HSE in the prior art is highly subjective, an imaging examination cannot reflect intracranial core lesions in real time and dynamically, is not related to a core biological mechanism of a disease, brain tissue samples are difficult to obtain, direct and effective indexes of intracranial disease states are scarce, and routine laboratory examinations are not specific for central nervous system pathologies and recovery of nerve functions. The application comprises application of CTRP4 in preparation of a herpes simplex encephalitis diagnostic reagent, and the diagnostic reagent is used for detecting the expression level of CTRP4 in a biological sample of a subject. The application of CTRP4 in preparation of the herpes simplex encephalitis diagnostic reagent can provide a highly specific, non-invasive and dynamic herpes simplex encephalitis condition assessment scheme, and solves the limitation problem of subjective diagnosis by doctors in traditional assessment.

One variation of a method for modeling neurological development includes: aggregating electroencephalography (EEG) data that comprise multiple EEG signals of each user in a set of users, EEG signals of each user recorded on multiple distinct dates, the set of users comprising a plurality of users of various known neurological statuses; identifying a synchronization pattern trend within the EEG data of the set of users; and correlating the synchronization pattern trend with neurological development within the set of users.

This invention provides an artificial dura mater material, its preparation method, and its applications, belonging to the field of biomedical technology. Addressing the shortcomings of traditional synthetic dura mater, this invention utilizes poly(L-lactide-caprolactone) (PLCL) with a specific concentration of RAPA, processed using electrospinning. It exhibits low porosity and a dense texture, inducing rapid endothelialization of the dura mater in the early stages of traumatic brain injury. Subsequently, with the release of RAPA, the material's porosity increases, facilitating the proliferation and growth of newly formed dura mater cells. Simultaneously, RAPA can prevent excessive proliferation of new endothelial cells and scar hyperplasia. It can selectively inhibit pathological proliferation without impairing necessary lymphatic drainage; while maintaining the physical structural integrity of the dura mater, it can promote neurological function repair.

The application provides an application of YAP in preparation of a drug for preventing or treating retinal ganglion cell injury, and proves that up-regulation of YAP expression or activity can significantly reduce the retinal oxidative stress level, inhibit the neuroinflammatory response, and reduce the number of RGC death, thereby effectively protecting the nerve function. The application provides a new treatment target for diseases characterized by RGC injury, such as traumatic optic neuropathy and glaucoma, and YAP or an expression promoter thereof can be used for preparing a drug for preventing, relieving and / or treating the diseases, and has an important clinical application prospect.